Stockholm3 is a blood test that combines protein markers, genetic markers and clinical data with an advanced algorithm in order to detect aggressive prostate cancer at an early stage.
The Stockholm3 test is an advanced, blood-based screening tool for prostate cancer that combines protein biomarkers, genetic risk profiling, and clinical data to assess the likelihood of aggressive disease.
Early detection is the key to successful treatment of prostate cancer.
The PSA test is that it misses between 30 and 50 percent of all aggressive cases of cancer.
Stockholm3 finds 100 percent more aggressive cases of cancer.
This improves the ability to detect and treat cancer at an early stage.
Stockholm3 reduces the risk of conducting unnecessary prostate biopsies by 50 percent.
A problem with the PSA test is that it is difficult to interpret, but the Stockholm3 test provides an answer with a clear and easy-to-interpret recommendation.
It is designed to find clinically significant cancers early while significantly reducing unnecessary biopsies compared to standard PSA testing.
Nearly half of the men aged 50 to 70 years have a very low risk profile and do not need to take a new test until after six years.
Stockholm3 also reduces health care costs by 17 to 28 percent.
The Stockholm3 test provides an answer with a clear and easy-to-interpret recommendation, making it easier to make decisions on potential further actions.
In the event of a negative answer the tested man shows low or normal risk of developing prostate cancer. A follow-up within six respectively two years will be recommended.
In the event of a positive test result a referral to a urologist for further evaluation will be recommended.
As with the PSA test all men that take the Stockholm3 test should be informed about any negative consequences of taking the test.
All men between the ages of 45 and 74, without previously known prostate cancer, are recommended to take the Stockholm3 test.
The Stockholm3 test has no proven add-value and the test is not advised for men who previously been diagnosed with prostate cancer.
The Stockholm3 test does not replace a biopsy for men undergoing active monitoring.
Unlike traditional tests that rely heavily on a single protein (PSA), Stockholm3 utilizes an algorithm to combine multiple indicators:Protein Biomarkers: Measures 5 key plasma proteins (total PSA, free PSA, hK2, MSMB, and MIC-1).
Genetic Markers: Analyzes over 100 genetic markers (single nucleotide polymorphisms) to assess inherited risk.
Clinical Data: Integrates the patient’s age, family history, and previous biopsy history.
Target DemographicAge: Men aged 45 to 74.
Eligibility: Recommended for men with a baseline PSA of at least 1.5 ng/ml and no previous prostate cancer diagnosis.
Key BenefitsBetter Accuracy: Studies (including large-scale trials in Europe and North America) show that Stockholm3 detects up to 90% of aggressive prostate cancer cases, outperforming standard PSA testing.
Fewer Unnecessary Biopsies: By improving specificity, the test can safely reduce benign or low-risk cancer biopsies by 40% to 50%, saving patients from painful and unneeded procedures.
Results provide actionable, easy-to-interpret categories (e.g., High, Low, or Normal risk), helping doctors determine if a patient needs an MRI or immediate specialist referral.
Availability: The test is widely validated, commercially available in Sweden, and gaining rapid adoption across various international healthcare systems.